- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00990847
Nebulized Procaterol Versus Nebule Salbutamol for the Treatment of Moderate Acute Asthma
October 6, 2009 updated by: PT Otsuka Indonesia
The Efficacy of Nebulized Procaterol Versus Nebulized Salbutamol for the Treatment of Moderate Acute Asthma: a Randomized, Double-blind, Parallel Group Study
The purpose of this study is to compare the efficacy and safety of nebule procaterol with nebule salbutamol in the treatment of moderate acute asthma.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
140
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Jakarta, Indonesia
- University of Indonesia/ Persahabatan Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years to 60 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with moderate acute asthma according to Global Initiative for Asthma (GINA) 1998 (Appendix 1). Patients with moderate acute asthma according to Modified Global Initiative for Asthma (GINA) 1998 (Patients with asthma score 5 - 11; PEFR ≤ 80% predicted)
- Patients of both gender aged 15 to 60 years
- Patients still have the ability to undergo examinations and give written informed consent
Exclusion Criteria:
- Pregnant and lactating women
- Smokers
- Patients with heart disease, hyperthyroidism, diabetes mellitus, COPD or other chronic diseases
- Patients with signs of severe infections
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Procaterol
Procaterol inhalation solution 50 micro g per 0.5 mL diluted in 2mL of NaCl 0.9%, so that the volume of the inhalation solution will be similar to that of the comparator drug.
The nebule solution will be administered 3 times, i.e. at times 0, 20 and 40 minutes.
|
|
Active Comparator: Salbultamol
Salbultamol inhalation solution for nebulization containing 2.5 mg in 2.5 mL aqueous solution.
The nebule solution will be administered 3 times, i.e. at times 0, 20 and 40 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference 5% from baseline in peak expiratory flow rate (PEFR)
Time Frame: 3 times every 20 minutes (at 0, 20 and 40 minutes)
|
3 times every 20 minutes (at 0, 20 and 40 minutes)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference 5% from baseline in asthma score
Time Frame: 3 times every 20 minutes (at 0, 20 and 40 minutes)
|
3 times every 20 minutes (at 0, 20 and 40 minutes)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Hadiarto Mangunnegoro, MD, Department of Pulmonology and Respiratory Medicine, Faculty of Medicine University of Indonesia/ Persahabatan Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2007
Primary Completion (Actual)
April 1, 2008
Study Completion (Actual)
August 1, 2008
Study Registration Dates
First Submitted
October 5, 2009
First Submitted That Met QC Criteria
October 6, 2009
First Posted (Estimate)
October 7, 2009
Study Record Updates
Last Update Posted (Estimate)
October 7, 2009
Last Update Submitted That Met QC Criteria
October 6, 2009
Last Verified
October 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Sympathomimetics
- Procaterol
Other Study ID Numbers
- 002-IOA-0601
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Moderate Acute Asthma
-
KoBioLabsNovotech (Australia) Pty LimitedCompletedModerate to Severe AsthmaAustralia
-
Societa Italiana di PneumologiaSocietà Italiana di Allergologia, Asma e Immunologia ClinicaRecruiting
-
SamA Pharmaceutical Co., LtdCompleted
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
Action Against Hunger USAUniversity of Washington; Ethiopian Public Health InstituteNot yet recruitingModerate Acute Malnutrition | Severe Acute Malnutrition
-
Microbiome Health Research InstituteUniversity of Cape TownTerminatedModerate Acute Malnutrition | Severe Acute MalnutritionSouth Africa
-
Eurofarma Laboratorios S.A.Not yet recruiting
-
Regeneron PharmaceuticalsSanofiCompletedAsthma | Moderate AsthmaUnited Kingdom
-
EmphycorpTerminatedModerate AsthmaUnited States
-
MedImmune LLCTerminatedModerate AsthmaUnited Kingdom
Clinical Trials on Procaterol, Salbultamol
-
Mahidol UniversityThai Otsuka Pharmaceutical Co., Ltd.Unknown
-
Shanghai Jiao Tong University School of MedicineUnknownCough Variant AsthmaChina
-
Intech Biopharm Ltd.Completed
-
Taiwan Otsuka Pharm. Co., LtdCompleted
-
Otsuka Pharmaceutical, Inc., PhilippinesOtsuka Pharmaceutical Co., Ltd.TerminatedPulmonary Disease, Chronic ObstructivePhilippines
-
Thammasat UniversityNot yet recruiting
-
Intech Biopharm Ltd.CompletedAsthma | Chronic Obstructive Pulmonary Disease (COPD)Taiwan
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed
-
Otsuka Pharmaceutical, Inc., PhilippinesCompleted